FibroBiologics, Inc. Common Stock (FBLG NASDAQ) stock market data APIs
$0.5312
-0(-0%)
as of September 16, 2025
Try our APIs with
free plan!
FibroBiologics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas.
Prev. Close
0.5312
Open
0.5295
High
0.5375
Low
0.5247
52 wk Range
0.523-3.89
Market Cap
22 587 K
Shares Outstanding
41 889 K
EPS
-0.12
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with FibroBiologics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get FibroBiologics, Inc. Common Stock data using free add-ons & libraries
Get FibroBiologics, Inc. Common Stock Fundamental Data
FibroBiologics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -15 886 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
FibroBiologics, Inc. Common Stock News
New
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on th...
FBLG: Closes Third Tranche of $5M…
By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing pre...
FibroBiologics reports 1H results
* FibroBiologics press release [https://seekingalpha.com/pr/20185766-fibrobiologics-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:FBLG [https://seekingalpha.co...
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
